Martin Tolar Email

Founder, President & CEO . Alzheon

Current Roles

Employees:
30
Revenue:
$3.2M
About
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com
Alzheon Address
111 Speen Street
null, null
United States
Alzheon Email

Past Companies

Alzheon, Inc.Founder, President & CEO
INDRC - International Neurodegenerative Disorders Research CenterFounder, Chairman of Executive Board
Alzheimer's Drug Discovery FoundationBusiness Advisory Board & Scientific Review Board

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.